Tags

Type your tag names separated by a space and hit enter

Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility.

Abstract

OBJECTIVE

Duodenal contents refluxing into the esophagus may be involved in the pathophysiology of gastroesophageal reflux disease (GERD). This study was performed to investigate whether medical treatment of GERD aimed at suppression of gastric acid production can prevent the development of complications, such as Barrett's metaplasia or poor esophageal body motility.

DESIGN

Retrospective study.

SETTING

University hospital.

PATIENTS

138 GERD patients were analyzed regarding the development of Barrett's metaplasia or poor esophageal body motility, despite intermittent or continuous treatment with H2 blockers or omeprazole.

MAIN OUTCOME MEASURES

The rate of patients with Barrett's metaplasia or poor esophageal body motility with or without effective medical treatment.

RESULTS

Barrett's metaplasia was found in 33.8% of patients receiving medical treatment, although it was not present when treatment was induced. This rate was 21.9% among patients who were not receiving therapy (not significant). In all, 41.9% of patients with medication had impaired esophageal body motility compared with 59.3% of patients not receiving treatment (P < 0.05), but these patients had a significantly shorter history of GERD.

CONCLUSIONS

Medical treatment with H2 blockers or omeprazole does not prevent the development of Barrett's metaplasia or poor esophageal body motility.

Links

Authors+Show Affiliations

,

2nd Department of Surgery, University of Innsbruck, Austria.

, , , ,

Source

MeSH

Anti-Ulcer Agents
Barrett Esophagus
Dose-Response Relationship, Drug
Esophageal Motility Disorders
Esophagoscopy
Esophagus
Follow-Up Studies
Gastric Acidity Determination
Gastroesophageal Reflux
Histamine H2 Antagonists
Humans
Manometry
Omeprazole
Retrospective Studies
Risk Factors

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

9128874

Citation

Wetscher, G J., et al. "Medical Treatment of Gastroesophageal Reflux Disease Does Not Prevent the Development of Barrett's Metaplasia and Poor Esophageal Body Motility." Langenbecks Archiv Fur Chirurgie, vol. 382, no. 2, 1997, pp. 95-9.
Wetscher GJ, Profanter C, Gadenstätter M, et al. Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbecks Arch Chir. 1997;382(2):95-9.
Wetscher, G. J., Profanter, C., Gadenstätter, M., Perdikis, G., Glaser, K., & Hinder, R. A. (1997). Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbecks Archiv Fur Chirurgie, 382(2), pp. 95-9.
Wetscher GJ, et al. Medical Treatment of Gastroesophageal Reflux Disease Does Not Prevent the Development of Barrett's Metaplasia and Poor Esophageal Body Motility. Langenbecks Arch Chir. 1997;382(2):95-9. PubMed PMID: 9128874.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. AU - Wetscher,G J, AU - Profanter,C, AU - Gadenstätter,M, AU - Perdikis,G, AU - Glaser,K, AU - Hinder,R A, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 95 EP - 9 JF - Langenbecks Archiv fur Chirurgie JO - Langenbecks Arch Chir VL - 382 IS - 2 N2 - OBJECTIVE: Duodenal contents refluxing into the esophagus may be involved in the pathophysiology of gastroesophageal reflux disease (GERD). This study was performed to investigate whether medical treatment of GERD aimed at suppression of gastric acid production can prevent the development of complications, such as Barrett's metaplasia or poor esophageal body motility. DESIGN: Retrospective study. SETTING: University hospital. PATIENTS: 138 GERD patients were analyzed regarding the development of Barrett's metaplasia or poor esophageal body motility, despite intermittent or continuous treatment with H2 blockers or omeprazole. MAIN OUTCOME MEASURES: The rate of patients with Barrett's metaplasia or poor esophageal body motility with or without effective medical treatment. RESULTS: Barrett's metaplasia was found in 33.8% of patients receiving medical treatment, although it was not present when treatment was induced. This rate was 21.9% among patients who were not receiving therapy (not significant). In all, 41.9% of patients with medication had impaired esophageal body motility compared with 59.3% of patients not receiving treatment (P < 0.05), but these patients had a significantly shorter history of GERD. CONCLUSIONS: Medical treatment with H2 blockers or omeprazole does not prevent the development of Barrett's metaplasia or poor esophageal body motility. SN - 0023-8236 UR - https://www.unboundmedicine.com/medline/citation/9128874/Medical_treatment_of_gastroesophageal_reflux_disease_does_not_prevent_the_development_of_Barrett's_metaplasia_and_poor_esophageal_body_motility_ L2 - http://www.diseaseinfosearch.org/result/2996 DB - PRIME DP - Unbound Medicine ER -